Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Xadago
Xadago 50 mg film-coated tablets Xadago 100 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 6
HOS-125754 · Präparat HOS-096139
Adverse reactions are ranked under headings of frequency using the following conventions: very
common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to
<1/1000), very rare (<1/10,000) and not known (cannot be estimated from the available data).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-09T12:57:00Z · SHA-256 48b01ba5b1179c2ba1e43605dbb52f4115246d6aa2dd76fd1814d41eff2382ed · Passage ddd8181eed2b3da1af89482c81429c96458182f8b68523e4b7d9017d930378af · Zeichen 1126–1404 im Abschnitt
Nebenwirkungen · Xadago
Xadago 50 mg film-coated tablets Xadago 100 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 6–8
HOS-125755 · Präparat HOS-096139
System Organ Very Common Uncommon Rare
Class common
Infections and Urinary tract infection Bronchopneumonia,
infestations furuncle,
nasopharyngitis,
pyoderma,
rhinitis,
tooth infection,
viral infection
Neoplasms Basal cell carcinoma Acrochordon,
benign, melanocytic naevus,
malignant and seborrhoeic keratosis,
unspecified (incl skin papilloma
cysts and
polyps)
Blood and Anaemia, Eosinophilia,
lymphatic leukopenia, lymphopenia
system disorders red blood cell
6
System Organ Very Common Uncommon Rare
Class common
abnormality
Metabolism and Decreased appetite, Cachexia,
nutrition hypertriglyceridaemia, hyperkalaemia
disorders increased appetite,
hypercholesterolaemia,
hyperglycaemia,
Psychiatric Insomnia Hallucination, Compulsions,
disorders depression, delirium,
abnormal dreams, disorientation,
anxiety, illusion,
confusional state, impulsive behaviour,
affect lability, loss of libido,
libido increased, obsessive thoughts,
psychotic disorder, paranoia,
restlessness, premature ejaculation,
sleep disorder sleep attacks,
social phobia,
suicidal ideation
Nervous system Dyskinesia Paraesthesia, Coordination abnormal,
disorders somnolenc balance disorder, disturbance in attention,
e, hypoaesthesia, dysgeusia,
dizziness, dystonia, hyporeflexia,
headache, head discomfort, radicular pain,
Parkinson' dysarthria, Restless Legs Syndrome,
s disease syncope, sedation
cognitive disorder
Eye disorders Cataract Vision blurred, Amblyopia,
scotoma, chromatopsia,
diplopia, diabetic retinopathy,
photophobia, erythropsia,
retinal disorder, eye haemorrhage,
conjunctivitis, eye pain,
glaucoma eyelid oedema,
hypermetropia,
keratitis,
lacrimation increased,
night blindness,
papilloedema,
presbyopia,
strabismus
Ear and Vertigo
labyrinth
disorders
Cardiac Palpitations, Myocardial infarction
disorders tachycardia,
sinus bradycardia,
arrhythmia
Vascular Orthostatic Hypertension, Arterial spasm,
disorders hypotensio hypotension, arteriosclerosis,
n varicose vein hypertensive crisis
Respiratory, Cough, Bronchospasm,
thoracic and dyspnoea, dysphonia,
mediastinal rhinorrhoea oropharyngeal pain,
7
System Organ Very Common Uncommon Rare
Class common
disorders oropharyngeal spasm
Gastrointestinal Nausea Constipation, Peptic ulcer,
disorders dyspepsia, retching,
vomiting, upper gastrointestinal
dry mouth, haemorrhage
diarrhoea,
abdominal pain,
gastritis,
flatulence,
abdominal distension,
salivary hypersecretion,
gastrooesophageal reflux
disease,
aphthous stomatitis
Hepatobiliary Hyperbilirubinaemia
disorders
Skin and Hyperhidrosis, Alopecia,
subcutaneous pruritus generalised, blister,
tissue disorders photosensitivity reaction, dermatitis contact,
erythema dermatosis,
ecchymosis,
lichenoid keratosis,
night sweats,
pain of skin,
pigmentation disorder,
psoriasis,
seborrhoeic dermatitis
Musculoskeletal Back pain, Ankylosing spondylitis,
and connective arthralgia, flank pain,
tissue disorders muscle spasms, joint swelling,
muscle rigidity, musculoskeletal pain,
pain in extremity, myalgia,
muscular weakness, neck pain,
sensation of heaviness osteoarthritis,
synovial cyst
Renal and Nocturia, Micturition urgency,
urinary dysuria polyuria, pyuria,
disorders urinary hesitation
Reproductive Erectile dysfunction Benign prostatic
system and hyperplasia,
breast disorders breast disorder,
breast pain
General Fatigue, Drug effect decreased,
disorders and asthenia, drug intolerance,
administration gait disturbance, feeling cold,
site conditions oedema peripheral, malaise,
pain, pyrexia,
feeling hot xerosis
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-09T12:57:00Z · SHA-256 48b01ba5b1179c2ba1e43605dbb52f4115246d6aa2dd76fd1814d41eff2382ed · Passage 1f5d98f854295dfdda5a6ed7e7d0f70a055a864536b8ea1368efb0538dc37855 · Zeichen 1407–10560 im Abschnitt
Nebenwirkungen · Xadago
Xadago 50 mg film-coated tablets Xadago 100 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 8–9
HOS-125756 · Präparat HOS-096139
8
System Organ Very Common Uncommon Rare
Class common
Investigations Weight decreased, Blood calcium
weight increased, decreased,
blood creatine blood potassium
phosphokinase decreased,
increased, blood cholesterol
blood triglycerides decreased,
increased, body temperature
blood glucose increased, increased,
blood urea increased, cardiac murmur,
blood alkaline cardiac stress test
phosphatase increased, abnormal,
blood bicarbonate haematocrit decreased,
increased, haemoglobin decreased,
blood creatinine international normalised
increased, ratio decreased,
electrocardiogram QT lymphocyte count
prolonged, decreased,
liver function test platelet count decreased,
abnormal, very low density
urine analysis abnormal, lipoprotein increased
blood pressure increased,
blood pressure
decreased,
ophthalmic diagnostic
procedures abnormal
Injury, Fall Foot fracture Contusion,
poisoning and fat embolism,
procedural head injury,
complications mouth injury,
skeletal injury
Social Gambling
circumstances
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-09T12:57:00Z · SHA-256 48b01ba5b1179c2ba1e43605dbb52f4115246d6aa2dd76fd1814d41eff2382ed · Passage f65d2a8a99514036d8165a35aeb66eff8ea550b3e4051c16829b0edaf5e6bf34 · Zeichen 10606–13390 im Abschnitt
Nebenwirkungen · Xadago
Xadago 50 mg film-coated tablets Xadago 100 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 9
HOS-125757 · Präparat HOS-096139
Description of selected adverse dreactions
Dyskinesia occurred early in treatment, was rated “severe”, led to discontinuation in very few patients
(approx. 1.5%), and did not require reduction of dose in any patient.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-09T12:57:00Z · SHA-256 48b01ba5b1179c2ba1e43605dbb52f4115246d6aa2dd76fd1814d41eff2382ed · Passage 6c88a4bcb1a754f58d4fb75f46c43d18e6f8206570b0cf94a61b425d67c6a33c · Zeichen 13392–13608 im Abschnitt
Nebenwirkungen · Xadago
Xadago 50 mg film-coated tablets Xadago 100 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 9
HOS-125758 · Präparat HOS-096139
Reporting of suspected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-09T12:57:00Z · SHA-256 48b01ba5b1179c2ba1e43605dbb52f4115246d6aa2dd76fd1814d41eff2382ed · Passage 822da43363cee11e87abeb55cf82453415269315377df150bb5de7dde8dd938f · Zeichen 13610–13650 im Abschnitt
Nebenwirkungen · Xadago
Xadago 50 mg film-coated tablets Xadago 100 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 9
HOS-125759 · Präparat HOS-096139
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-09T12:57:00Z · SHA-256 48b01ba5b1179c2ba1e43605dbb52f4115246d6aa2dd76fd1814d41eff2382ed · Passage 591ce3aa6d6555db7032d0551da929e990b92080da2928085827a75c666ec353 · Zeichen 13652–13966 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.